Gene Therapy Strategies for Hepatocellular Carcinoma (HCC): Current Landscape and Future Directions

Area of Science:

• Hepatology
• Oncology
• Gene Therapy

Background:

• The liver is crucial for metabolism; advanced liver diseases impair this function, complicating drug treatment due to toxicity and reduced efficacy.
• Hepatocellular carcinoma (HCC), often diagnosed late, is challenging to treat with current standards like immunotherapy or tyrosine kinase inhibitors (TKIs).
• Existing HCC treatments offer limited survival benefits (~2 years), with low response rates for immunotherapy (27%) and rapid resistance to TKIs.

Purpose of the Study:

• To review recent advancements in gene therapy for managing advanced hepatocellular carcinoma (HCC).
• To highlight gene therapy's potential to extend survival and enhance the quality of life for HCC patients.
• To present gene therapy as a viable alternative to current treatment modalities for liver cancer.

Main Methods:

• Review of recent scientific literature on gene therapy applications in liver disease and HCC.
• Analysis of studies focusing on gene therapy's efficacy, safety, and patient outcomes.
• Synthesis of data regarding the potential of gene therapy to overcome challenges in advanced HCC management.

Main Results:

• Gene therapy approaches are demonstrating significant advancements in managing HCC.
• Emerging evidence suggests gene therapy can extend survival benefits for patients with advanced liver cancer.
• The reviewed literature indicates improved quality of life associated with gene therapy interventions in HCC.

Conclusions:

• Gene therapy presents a promising frontier for treating advanced liver diseases, particularly HCC.
• Despite not yet being FDA-approved for HCC, gene therapy shows considerable potential to overcome limitations of current treatments.
• Further research and clinical translation of gene therapy could revolutionize HCC management and patient outcomes.